Previous 10 | Next 10 |
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide. The company today announced that recruiting is underway for its phase 2 trial of FSD201 ...
FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“ FSD Pharma ” or the “ Company ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announce...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, is front and center in a recent InvestmentPitch Media Video. The video spotlighted FDS Pha...
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical T...
FSD Pharma ( NASDAQ: HUGE ) said it submitted a clinical trial application (CTA) seeking to start a phase 1 trial of Lucid-MS to treat multiple sclerosis (MS). Lucid-MS is a first-in-class neuroprotective compound and in preclinical models has shown to prevent myelin degradation (...
Company Seeking to Initiate Phase 1 Clinical Trial for its First-in-Class Multiple Sclerosis Drug Candidate FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio o...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has announced a share repurchase program. The company’s board of directors approved...
FSD Pharma ( NASDAQ: HUGE ) shares gained ~13% premarket on Friday after the biopharmaceutical company announced a normal course issuer bid to repurchase up to 1,925,210 of its Subordinate Class B Voting Shares over the next 12 months. That represents ~5% of the company’...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development in...
News, Short Squeeze, Breakout and More Instantly...
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has been featured in a news report published by 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of finan...
Denver, Colorado--(Newsfile Corp. - July 25, 2024) - 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report highlighting functional beverage market developments, featuring FSD Pharma (NASDAQ: HUGE...
2024-07-25 08:16:52 ET DENVER, Colo., Jul 25, 2024 ( 247marketnews.com )- Coca-Cola (NYSE: KO ) , FSD Pharma (NASDAQ: HUGE ), and Celsius Holdings, Inc. (NASDAQ: CELH ) Sometimes, there are some winning streaks that are so strong that even...